Antifibrosis treatment by inhibition of VEGF, FGF, and PDGF receptors improves bladder wall remodeling and detrusor overactivity in association with modulation of C‐fiber afferent activity in mice with spinal cord injury

2021 ◽  
Author(s):  
Joonbeom Kwon ◽  
Eun‐Ju Lee ◽  
Hyun‐Jung Cho ◽  
Ji‐Ae Jang ◽  
Min‐Su Han ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Detrusor Overactivity ◽  
Bladder Wall ◽  
Afferent Activity ◽  
Cord Injury ◽  
C Fiber

Moxibustion attenuates neurogenic detrusor overactivity in spinal cord injury rats by inhibiting M2/ATP/P2X3 pathway

2021 ◽  
Author(s):  
Lu Wang ◽  
Yuan-Bo Fu ◽  
Yi Liu ◽  
Na-Na Yang ◽  
Si-Ming Ma ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Detrusor Overactivity ◽  
Bladder Function ◽  
Potential Candidate ◽  
Neurogenic Detrusor Overactivity ◽  
Afferent Activity ◽  
Sprague Dawley ◽  
Pressure Threshold ◽  
Cord Injury

Abstract Background Activation of muscarinic receptors located in bladder sensory pathways is generally considered to be the primary contributor for driving the pathogenesis of neurogenic detrusor overactivity following spinal cord injury. The present study is undertaken to examine whether moxibustion improves neurogenic detrusor overactivity via modulating the abnormal muscarinic receptor pathway. Methods Female Sprague-Dawley rats were subjected to spinal cord injury with T9-10 spinal cord transection. Fourteen days later, animals were received moxibustion treatment for one week. Urodynamic parameters and pelvic afferents discharge were measured. Acetylcholine and adenosine triphosphate content in the voided cystometry fluid were determined. Expressions of M2, M3 and P2X3 receptor in the bladder mucosa were evaluated. Results Moxibustion treatment prevented the development of detrusor overactivity in SCI rats, with an increase in the intercontraction interval and micturition pressure threshold and a decrease in afferent activity during filling. The expression of M2, but not M3, was markedly suppressed by moxibustion, accompanied by a reduction in the level of ATP and P2X3. M2 receptor antagonist methoctramine hemihydrate had similar effects to moxibustion on bladder function and afferent activity, while the M2-preferential agonist oxotremorine methiodide abolished the beneficial effects of moxibustion. Conclusions Moxibustion is a potential candidate for treatment of neurogenic bladder overactivity in a rat model of spinal cord injury possibly through inhibiting the M2/ATP/P2X3 pathway.

scholarly journals 200 U vs. 300 U Botulinum Toxin a Injections for Patients with Neurogenic Detrusor Overactivity Secondary to Spinal Cord Injury

2020 ◽  
Vol 3 (1) ◽  
pp. 1-4
Author(s):  
Lin JM ◽  
◽  
Hui Chen ◽  
Liu QL ◽  
Huang MP ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Urinary Incontinence ◽  
Botulinum Toxin ◽  
Detrusor Overactivity ◽  
Botulinum Toxin A ◽  
Control Group ◽  
Neurogenic Detrusor Overactivity ◽  
Toxin A ◽  
Cord Injury

Objective: To evaluate the d the safety and efficacy of 200 U vs. 300 U botulinum toxin A (BTX-A) injections for patients with neurogenic detrusor overactivity (NDO) secondary to spinal cord injury (SCI). Methods: We retrieved the data for the patients who receive a single dose into the detrusor of BTX-A (300 U or 200 U). The clinical outcome included maximum detrusor pressure (Pdetmax) during cystometry, voiding volume, urinary incontinence (UI) episodes between CICs per 24 hour, and complete dryness. Related adverse events were recorded. Results: From July 2015 to June 2017, 28 cases received 300 U BTX-A injections (experiment group) while 19 cases received 200U BTX-A injections (control group). There were no significant differences in baseline evaluation items (gender, age, duration of spinal cord injury, level of neurological injury, AIS scores) between the two groups. There were significant improvement in Pdetmax, UI and I-QoL from baseline in the two groups. Patients in experiment group had statistically greater improvement than those in the control group for Pdetmax (-32.09 cm H2O vs. -28.02 cm H2O, P = 0.016), mean urinary incontinence episodes (-6.18/d vs. -5.01/d, P = 0.042), complete dryness (11 vs. 2, P = 0.031), mean voiding volume (160.52 ml vs. 133.66 ml, P <0.001), and I-QoL (28.53 vs. 20.41, P <0.001). Conclusion: Preliminary results indicate that 300 U BTX-A is more effective than 200 U BTX-A for SCI patients with NDO.

Sign in / Sign up

Export Citation Format

Share Document